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Purpose:  To  identify  the  mutation  in  polyadenylate-binding  protein  nuclear  1  gene  (PABPN1,  previously  termed
PABP2) in a Chinese family with autosomal, dominantly inherited oculopharyngeal muscular dystrophy (OPMD).
Methods: Clinical and ophthalmologic examinations were conducted on available living family members from three
generations. Genomic DNA was extracted from peripheral blood leukocytes of every available family member, and the
fragment flanking the (GCG)n of the PABPN1 gene was amplified by PCR. Mutations were screened by DNA sequencing.
Photographs of deceased family members were examined for signs of OPMD.
Results: Clinical features of OPMD were found in all patients in generation II except the youngest sister, and no clinical
manifestations were found in generation III. Mutation sequencing demonstrated that (GCG)6 in the wild PABPN1 gene
was expanded to heterozygous (GCG)11 in all affected family members and in some but not all unaffected members.
Conclusions: In a Chinese family with autosomal dominantly inherited OPMD, a heterozygous (GCG)11 expansion was
identified in all affected family members and in several young unaffected members.
Oculopharyngeal  muscular  dystrophy  (OPMD)  is  an
autosomal dominant late-onset disease that is characterized by
progressive bilateral ptosis, dysphagia, and dysarthria [1]. It
is a rare disease with a prevalence of approximately 1/100,000
worldwide [2]. In 1962, Victor et al. [3] first described a
family with OPMD; nine members of three generations were
known to be affected (OPMD; OMIM 164300). In a large
cohort in New Mexico, ptosis was reported to be the first
symptom to appear, sometimes concurrently with dysphagia.
Pharyngeal weakness and gait abnormalities were common
and occurred later than ocular weakness [4]. Although the
disease is mainly inherited in an autosomal dominant manner,
an autosomal recessive mode of transmission was suggested
as early as 1975 [5].
In 1998, Brais et al. [6] identiﬁed a stable trinucleotide
repeat expansion at the N-terminus of the PABPN1 gene on
chromosome 14q11 in affected families. The normal allele is
(GCG)6 repeat-encoding a polyalanine (polyA) stretch at the
5′ end, but the dominant expansion can range from (GCG)8 to
(GCG)13, and the autosomal recessive form of the disease
occurs as a single GCG expansion, (GCG)7. Adjacent to the
(GCG)6  repeat,  there  is  a  GCA  GCA  GCA  GCG  coding
sequence.  GCG  and  GCA  both  encode  alanine  molecules
(Ala), so the wild PABPN1 protein has a stretch of 10 Ala,
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whereas the mutated PABPN1 in dominant OPMD has 12–17
Ala in the N-terminal domain.
To date, Hung-Chou Kuo et al. [7] have reported the
(GCG)6(GCA)(GCG)4 mutation in a Taiwanese family, and a
Chinese Malaysian case with the (GCG)9 mutation has been
reported by Khean Jin Goh et al. [8]. Recently, You et al. [9]
reported  the  identical  mutation,  (GCG)9(GCA)3GCG,  in  a
mainland Chinese family with OPMD. Herein, we describe
another mainland Chinese family with an autosomal dominant
form  of  OPMD,  in  which  we  detected  a  heterozygous
(GCG)11(GCA)3GCG expansion.
METHODS
Patient and family data: The proband (II-5) in this family
presented with ptosis. She was 54 years old, and bilateral
eyelid drooping had gradually developed since age 47. She
did not notice the drooping until it affected her vision. She had
to tilt her head backward and use the frontalis muscle to raise
her eyelid, severely affecting cosmesis. Later, the patient also
had dysphagia and dysarthria. The pedigree (Figure 1) was
constructed based on interviews with family members and
examination of photographs of deceased family members. All
members of generation II were affected, except the youngest
sister  (II-7),  who  was  41  years  old.  None  of  the  nine
individuals in generation III (aged 12–41 years) was affected
yet.
Genomic  DNA  preparation:  All  procedures  followed  the
tenets of the Helsinki declaration, approval was obtained from
the Local Research Ethics Committee of Zhejiang University,
and written informed consent was obtained from all patients
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1350in the study. Blood specimens (4 ml) from all of the patients
and available family members (marked with an asterisk in
Figure  1)  were  collected  in  a  BD  Vacutainer  (Becton-
Dickinson, Franklin Lakes, NJ) containing EDTA. Genomic
DNA was extracted from leukocytes of peripheral blood using
a QIAmp blood kit (Qiagen, Hilden, Germany).
PCR and DNA sequencing: A pair of special primers (forward:
5′-GGC AGG CAG CTT GAC TAA TG-3′; reverse: 5′-CTC
AGA  CTC  CAG  GCC  GTT  CTA-3′)  were  designed  to
amplify the fragment flanking the GCN repeat. The cycling
conditions were 98 °C for 30 s, followed by 35 cycles at 98 °C
for 10 s, 57 °C for 5 s, 72 °C for 20 s, and finally 72 °C for 5
min  and  20  °C  for  5  min,  using  PrimeSTAR  HS  DNA
polymerase  and  2×  PrimeSTAR  GC  Buffer  (Mg2+  Plus;
TaKaRa,  Japan).  The  PCR  product  was  isolated  by
electrophoresis on a 2% agarose gel and sequenced using the
BigDye Terminator Cycle sequencing kit V 3.1 (ABI Applied
Biosystems,  Foster  City,  CA)  on  an  ABI  PRISM  3730
Sequence  Analyzer,  according  to  the  manufacturer’s
directions.
RESULTS
Clinical  analysis:  Clinical  and  genetic  information  was
obtained from 12 family members (11 women, 1 man; Table
1). All of the affected family members had begun to develop
bilateral  and  symmetric  eyelid  drooping  in  approximately
their fifth decade, followed later by dysphagia and dysarthria,
and the affected members recalled that their father (I-1) also
developed drooping eyelids when he was approximately 50
years old. The oldest sister (II-1) could barely see, since even
when she used the frontalis muscle, the fissure of palpebrae
was only 3 mm and the levator function was 1 mm (Figure 2).
She had difficulty swallowing solid foods, such as certain
vegetables. II-4 died in a traffic accident at age 40, and he had
not developed severe ptosis by that time.
Because of the symmetric nature of ophthalmoplegia,
these patients did not complain of diplopia. They might have
been  unaware  of  their  decreased  motility  until  it  became
severe.
Molecular  genetic  analysis:  After  sequencing  the  PCR
product of the PABPN1 gene, we identified a heterozygous
(GCG)11  repeat  in  all  the  affected  individuals  of  the  II
generation. The youngest sister (II-7, 41 years old), who was
Figure  1.  Pedigree  of  the  family.
Squares  represent  male.  Circles
represent females. Affected individuals
are  indicated  by  black  circles  and
squares.  Unaffected  individuals  are
indicated by white circles and squares.
The arrow points at II-5, the proband.
Diagonal  lines  indicate  the  deceased.
*The patient has been examined.
TABLE 1. CLINICAL DATA AND GCG EXPANSION OF AVAILABLE FAMILY MEMBERS.
Patient
number
Gender Age (years) Initial
symptom
Age of onset (years) (GCG)
expansion
Ptosis Dysphagia Dysarthria
I-2 F 87 - - - - N
II-1 F 63 Ptosis 50 51 52 11/6
II-2 F 61 Ptosis 48 50 50 11/6
II-3 F 60 Ptosis 50 51 51 11/6
II-5 F 54 Ptosis 47 50 50 11/6
II-6 F 52 Ptosis 45 48 50 11/6
II-7 F 41 - - - - N
III-2 F 33 - - - - 11/6
III-3 F 32 - - - - 11/6
III-4 M 30 - - - - N
III-7 F 22 - - - - N
III-9 F 15 - - - - N
                Abbreviations: F: female; M: male; +: present; -: absence; N: normal.
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1351not yet affected, revealed a normal allele. In the III generation
(ages 12–41 years), no family members were affected, but
among the examined members, III-2 and III-3 showed the
same  heterozygous  (GCG)11  repeat  as  the  affected  family
members; other individuals showed a normal trinucleotide
repeat  (GCG)6.  The  mutation  was  not  detected  in  100
unrelated  Chinese  people  without  OPMD,  who  served  as
controls (Figure 3).
DISCUSSION
Based  on  the  family  history,  clinical  manifestations,  and
molecular genetic analysis, our family was easily diagnosed
with  OPMD  inherited  in  an  autosomal  dominant  manner.
Genetic diagnosis is very important for patients suspected of
having  OPMD.  Although  creatine  kinase  and  L-lactate
dehydrogenase  are  reported  to  be  generally  moderately
increased in most patients with OPMD, the patients in our
study demonstrated normal levels (data not shown), as has
been reported in two Japanese families heterozygous for the
(GCG)11(GCA)3GCG allele with OPMD [10]. It is unknown
why the elevation of serum creatine kinase is absent only in
Asian (GCG)11 expansion mutation patients.
OPMD  occurs  worldwide,  particularly  in  the  French-
Canadian population. Barbeau [11] showed that all of the
numerous reported French-Canadian cases could be traced
back to a single ancestor who emigrated from France in the
1600s. Currently, several types of (GCG)n expansion have
been reported, ranging from (GCG)8–13, with (GCG)9 being
seen most frequently. The (GCG)11 type had previously been
Figure 2. Photograph of II-5. She is 63
years old, has had gradual progressive
ptosis since she was 50, and suffers a
facial weakness.
Figure  3.  PCR  product  sequencing
chromatograms.  A:  The  patient’s
heterozygous  (GCG)11  expansion
mutation is shown; the red arrow points
to the start of the frameshift, and before
it are the normal (GCG)6 sequences. The
heterozygous  alleles  are  bimodal  and
marked  “N”. B :  The  wild-type
PABPN1 gene sequence from a healthy
Chinese people is shown.
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1352reported by Nagashima et al. [10] and Uyama et al. [12] in
three Japanese families.
Nagashima et al. described a big family with 54 members,
ten  of  whom  were  affected  through  three  generations.
Bilateral ptosis developed in the fourth and fifth decades in
the lives of the affected family members, who later developed
diplopia,  nasal  voice,  dysphagia,  and  muscle  weakness.
Uyama et al. [12] reported two unrelated families, including
30 individuals affected by OPMD through four generations.
They developed bilateral ptosis, most of them in their fifth
decade, followed by dysphagia and limb weakness. All three
families had disease severity, for example, onset of ptosis,
similar to ours. If haplotype, including the number of GCG
repeats,  is  identical  among  those  families,  those  families
might have a common ancestor, and we are conducting further
research. It should be noted that the (GCG)7 allele can act as
a recessive mutation. PABPN1 gene is the first example of a
relatively frequent allele that can act either as a modifier of a
dominant phenotype or as a recessive mutation [5].
Although  most  published  reports  have  described  the
insertion as (GCG)n, some studies have identified GCA repeat
within the expanded GCG sequence [13–15], and this is seen
mainly  in  the  English  population.  Besides  the  insertion
mutations, a special point mutation was reported by Robinson
et al. [16]. The mutation was a c.35G>C base change resulting
in a glycine-to-alanine substitution at amino acid position 12
(p.Gly12Ala). Thus, the 10 alanine-glycine-2 alanine was in
lieu of 13 contiguous alanines, which is the cause of disease
in the common triplet repeat expansion mutation.
Trinucleotide  expansions  are  common  in  human
pathologies. They can be classified according to the amino
acid they code for: polyglutamine (polyQ) repeat diseases and
polyalanine  (polyA)  repeat  diseases  [17].  PolyQ  diseases
include  Huntington’s  disease,  spinobulbar  muscular
dystrophy, spinocerebellar ataxias types 1,2,3 (or Machado-
Joseph disease), and so forth [18]. The polyQ disease often
contains a large group of trinucleotide repeats (>35), whereas
OPMD is a unique disease that contains short trinucleotide
expansions (>2) but shares the features of polyQ and other
polyA diseases. Their common feature is protein misfolding
and subsequent aggregation [19]. The mutation is thought to
confer a toxic gain-of-function on the protein. Abu-Baker et
al. [17] have recently proposed that the expansion of the polyA
repeat  in  mutant  PABPN1  protein  causes  misfolding  and
exposes  the  hydrophobic  alanine  stretch,  which  would
otherwise be buried inside the protein in the wild-type form.
Thus, the longer the polyA stretch is, the more exposed the
hydrophobic region is. Hill et al. [20]reported that in the
Caucasian population in South England, the onset age of the
most dominant form of OPMD, of which expansions range
from(GCG)8 to (GCG)13, ranges from 40 to 70 years, with a
mean of 51 years. However, in the recessive models, of which
the expansion is (GCG)7, the age of onset is always between
69 and 74 years [2]. Repeat length appears to correlate with
disease severity, suggesting a relationship between genotype
and phenotype. The wild PABPN1 gene encodes for 10 Ala
residues in protein, whereas the mutant alleles in our patient
encode 15 Ala instead of 10. Thus, the number of alanine
residues in our patients are equivalent to those reported to be
generated  by  the  (GCG)6(GCA)3(GCG)2(GCA)3GCG
mutation [21].
Another  contrast  between  polyA  and  polyQ  is  the
mutational  mechanism.  In  polyQ  diseases,  polymerase
slippage  has  long  been  assumed  to  be  the  mechanism.
Polymerase slippage means the slipping of DNA polymerase
III from the DNA template strand at the repeat region and its
subsequent  reattachment  at  a  more  distant  site  during
replication. Polymerase slippage can cause the newly created
DNA  strand  to  contain  an  expanded  section  of  DNA.
However, in the mutation of OPMD, the expansions are small
and  stable  through  mitosis  and  meiosis,  making  unequal
recombination  more  likely  [22];  this  is  a  rare  event,
accounting  for  the  stability  of  mutations  over  many
generations, as suggested by Nakamoto et al. [23].
In conclusion, we have identified a recurrent, short GCG
expansion (GCG)11 in the PABPN1 gene in an Asian family
with a phenotype characterized by ptosis as the first symptom.
This is the first report of a Chinese family with OPMD caused
by the (GCG)11 mutation of the PABPN1 gene. Molecular
genetic analysis is a valuable method for the diagnosis of
OPMD.
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